-
2008
28 August 2008: Announcement no. 2, 2008: Zealand Pharma today announced that Dr. David H...
-
Product Pipeline
Zealand's Pipeline comprises 1 compound in phase III, 2 compounds in phase II, 3 compounds ...
2002
Eloff, B. C., Gilat, E. and Rosenbaum, D. S.:
Gap Junction Modifier ZP123 Inhibits Acidosis-Induced Conduction Slowing
Poster at American Heart Association Scientific Sessions 2002, Chicago, USA, November 17-20, 2002.
Circulation, 2002, 106, No. 19 (Suppl. II), p II-87, Abstract 440
Jonassen, T., Hadrup, N., Broend, L., Christensen, S., Nielsen, S., and Petersen, J. S.:
The aquaretic effect of the nociceptin analogue ZP120C is associated with marked downregulation of aquaporin 2.
Oral presentation at American Heart Association Scientific Sessions 2002, Chicago, USA, November 17-20, 2002.
Circulation, 2002, 106, No. 19 (Suppl. II), p II-135, Abstract 680
Petersen, J.S., Thorkildsen, C., Lundgren, K. and Neve, S.:
ZP10 - A new GLP-1 agonist that prevents diabetes progression and increases insulin mRNA expression in db/db mice.
38th Annual Meeting of the European Association for the Study of Diabetes (EASD) Budapest, Hungary; 1st - 5th September 2002
Diabetologia, 2002, 45 (Suppl. 1), A147, Abstract no. 447.
Poster presentation
Kjølbye, A.L., Holstein-Rathlou, N.-H. and Petersen, J.S.:
Anti-arrhythmic Peptide N-3-(4-Hydroxyphenyl)propionyl-Pro-Hyp-Gly-Ala-Gly-OH Reduces Dispersion of Action Potential Duration During Ischemia/Reperfusion in Rabbit Hearts.
J. Cardiovasc. Pharmacol. 2002. 40, 770–779
Regoli, D., Calo’, G., Rizzi, A., Rizzi, D., Marzola, G., Larsen, B.D.:
Pharmacological characterization of the novel nociceptin/orphanin FQ receptor ligand, ZP120: In vitro and in vivo studies in mice.
XIVth World Congress of Pharmacology, San Francisco, USA, July 7-12, 2002.
The Pharmacologist, 2002, 44 (2), suppl. 1, A101-A102, abstract 65.6
Rizzi, A., Rizzi, D., Marzola, G., Regoli, D., Larsen, B.D., Petersen, J. and Calo', G.:
Pharmacological characterization of the novel nociceptin/orphanin FQ receptor ligand, ZP120: in vitro and in vivo studies in mice.
Br. J. Pharmacol. 2002. 137, 369-374.
Kapusta, D.R., Calo’, G. and Kenigs, V.A.:
Peripheral administration of partial agonists of the nociceptin opioid peptide (NOP) receptor produce water diuresis in conscious rats.
Experimental Biology 2002 Meeting, New Orleans, LA, USA, April 2002
FASEB J. 16:A841, 2002. Poster no. 640.21
Kapusta, D.R., Kenigs, V.A., Vinge, M.M., Hansen, C., Meier, E., Thorkildsen, C., and Petersen, J.S:
ZP120C, is a peripherally acting nociceptin analogue with water diuretic and potassium sparing properties.
Experimental Biology 2002 Meeting, New Orleans, LA, USA, April 2002
FASEB J. 16:841, 2002. Poster no. 640.23
Jonassen, T.E.N., Græbe, M., Staahltoft,. D., Christensen, S. and Petersen, J. S.:
Aquaretic effect of a novel nociceptin analogue ZP120C.
Experimental Biology 2002 Meeting, New Orleans, LA, USA, April 2002
FASEB J. 16:A51, 2002. Poster no. 105.3
Thorkildsen, C., Petersen, J.S.,Neve, S.:
ZP10 – a new GLP-1 agonist that increases insulin mRNA expression.
Nedergaard Symposium, Odense, Denmark, January 24, 2002 (Abstract)
Poster presentation
Kapusta, D.R., Kenigs, V.A., Vinge, M.M., Thorkildsen, C., Petersen, J. S.:
ZP120: A new peripherally acting nociceptin analogue with water diuretic and potassium sparing properties.
Nedergaard Symposium, Odense, Denmark, January 24, 2002 (Abstract)
Poster presentation
Tip a friend
Fill in the form below to tip a friend about this page.
Subscribe
When this page is updated you will be updated by e-mail.